Acadia Pharmaceuticals announced that the U.S. Food and Drug Administration approved DAYBUE STIX, a dye‑ and preservative‑free powder formulation of trofinetide for treating Rett syndrome in patients two years and older. The approval expands the drug’s delivery options beyond the existing oral solution, offering a more convenient and potentially more compliant treatment for patients and caregivers. The new formulation is expected to maintain the same efficacy and safety profile as the current product, while broadening Acadia’s commercial reach in the Rett syndrome market.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.